Quantamental Technologies LLC Makes New Investment in Codexis, Inc. (NASDAQ:CDXS)

Quantamental Technologies LLC bought a new position in shares of Codexis, Inc. (NASDAQ:CDXS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,393 shares of the biotechnology company’s stock, valued at approximately $44,000.

Other institutional investors have also recently bought and sold shares of the company. New York State Common Retirement Fund lifted its position in shares of Codexis by 22.6% during the 1st quarter. New York State Common Retirement Fund now owns 61,280 shares of the biotechnology company’s stock worth $1,258,000 after buying an additional 11,280 shares in the last quarter. Pratt Collard Advisory Partners LLC lifted its position in shares of Codexis by 14.9% during the 2nd quarter. Pratt Collard Advisory Partners LLC now owns 48,107 shares of the biotechnology company’s stock worth $887,000 after buying an additional 6,250 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Codexis during the 1st quarter worth approximately $6,838,000. Spark Investment Management LLC lifted its position in shares of Codexis by 21.7% during the 1st quarter. Spark Investment Management LLC now owns 202,700 shares of the biotechnology company’s stock worth $4,161,000 after buying an additional 36,100 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in shares of Codexis during the 2nd quarter worth approximately $2,855,000. 87.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CDXS stock traded up $0.16 during trading hours on Friday, hitting $14.36. 445,970 shares of the company were exchanged, compared to its average volume of 592,707. The firm has a fifty day simple moving average of $14.80 and a 200 day simple moving average of $18.31. The company has a current ratio of 6.30, a quick ratio of 6.26 and a debt-to-equity ratio of 0.26. Codexis, Inc. has a 52-week low of $12.68 and a 52-week high of $23.05.



Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). Codexis had a negative return on equity of 21.60% and a negative net margin of 23.13%. The company had revenue of $12.32 million for the quarter, compared to analysts’ expectations of $14.90 million. Sell-side analysts anticipate that Codexis, Inc. will post -0.21 earnings per share for the current year.

In other news, Director Bernard J. Kelley sold 14,684 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $13.87, for a total transaction of $203,667.08. Following the completion of the sale, the director now owns 226,868 shares in the company, valued at approximately $3,146,659.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John J. Nicols purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $13.30 per share, with a total value of $133,000.00. Following the purchase, the insider now owns 1,082,679 shares in the company, valued at $14,399,630.70. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 58,000 shares of company stock valued at $634,300. 10.70% of the stock is currently owned by company insiders.

Several research firms have commented on CDXS. BidaskClub cut shares of Codexis from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 15th. HC Wainwright reissued a “buy” rating and set a $22.50 target price on shares of Codexis in a research report on Thursday, August 8th. Finally, Zacks Investment Research cut shares of Codexis from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Two analysts have rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Codexis presently has an average rating of “Buy” and an average price target of $21.58.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Further Reading: What is Cost of Debt?

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.